Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Weekly Docetaxel Concurrent Chemoradiotherapy Versus Cisplatin in Locorgionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Jun Liao

Citation

Annals of Oncology (2018) 29 (suppl_9): ix94-ix104. 10.1093/annonc/mdy438

Authors

J.F. Liao

Author affiliations

  • Radiation Oncology, Sun Yat-sen University Cancer Center, 510000 - Guangzhou/CN
More

Resources

Background

Previous study has reported taxane-based concurrent therapy had equivalent efficacy to platinum in head and neck squamous cell carcinom. However, studies about concurrent chemoradiation of docetaxel alone in NPC are limited.This study aimed to compare the effectiveness and toxicities of weekly docetaxel versus tri-weekly cisplatin concurrent chemoradiotherapy for locoregionally advanced NPC.

Methods

From January 2010 to December 2014, patients with newly diagnosed locoregionally advanced nasopharyngeal carcinoma receiving either weekly docetaxel or tri-weekly cisplatin were retrospectively reviewed. Propensity score matchingan alysis was used to balance baseline characteristics between treatment arms. Data from 962 patients were included in the analysis, and the propensity matched cohort included 448 patients in total.

Results

The median follow-up duration is 47 months among the matched cohort.3-year nodal recurrence-free survival was significantly improved for patients treated with docetaxel compared to cisplatin (HR,0.33; 95%CI 0.12 to 0.90, P = 0.020), however,there were no differences in 3-year overall survival, local relapse-free survival, and distant-metastasis free survival between two groups. In subgroup analysis, cisplatin showed a trend towards improving distant metastasis free survival (89.2%vs.78.1%,P=0.075) which did not reach statistical significance in patients with pretreatment levels of Epstein-Barr VirusDNA≥4000 copy/mL. Significant higher incidence of grade 3/4 radiodermatitis (7.1%vs.1.6%,P=0.001) and mucositis (78.8%vs.45.5%,P<0.001)were observed in docetaxel group, but renal injury (1.8%vs. 15.1%, P < 0.01),vomiting(19.6% vs 93%, P < 0.01), hepatic injury (18.8%vs.31.3%,P<0.027), and grade 3/4 hematologicaltoxicity (2.2%vs.14.3%, P < 0.01) were more common in cisplatin group.

Conclusions

Weekly low-dose docetaxel concurrent chemoradiotherapyis an effective and toxicity tolerable method for locally advanced NPC.It provides a survival benefit mainly by improving regional control especially for patients with low EBV DNA levels. As forpatients with EBV DNA ≥4000 copy/mL, concurrent cisplatin seemsto be more efficacious.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sun Yat-sen University Cancer Center.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings